/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
0
0
David Anderson
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
David Anderson2023-09-18 15:23:232023-09-19 08:07:25Peptilogics Reports Positive 180-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients with Periprosthetic Joint Infection (PJI)
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
0
0
David Anderson
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
David Anderson2023-05-23 15:56:282023-05-23 16:03:15Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients with Periprosthetic Joint Infection (PJI)
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
0
0
David Anderson
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
David Anderson2023-04-06 05:00:192023-04-06 05:00:25Peptilogics Completes Phase 1b Trial Enrollment and Will Present Interim Top-line Safety and Tolerability Data of PLG0206 in Patients Undergoing DAIR for the Treatment of Periprosthetic Joint Infection After a Total Knee Arthroplasty at ECCMID 2023
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
0
0
eallison
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
eallison2023-02-23 16:34:512023-02-23 16:43:50Peptilogics Hosting Panel Discussion with Leading Industry Experts on the High Unmet Medical Need and Opportunity in Periprosthetic Joint Infections (PJI)
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
0
0
David Anderson
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
David Anderson2022-10-19 16:48:382022-10-19 16:57:26Peptilogics to Present Data at IDWeek 2022 on PLG0206, an Engineered Antimicrobial Peptide Targeting Bacteria Causing Periprosthetic Joint Infection
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
0
0
David Anderson
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
David Anderson2022-10-06 16:53:592022-10-06 16:57:40Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206 at the 2022 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
0
0
David Anderson
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
David Anderson2022-10-05 13:25:452022-10-06 16:56:54Peptilogics Announces First Patient Dosed in Phase 1b Study of PLG0206 for Periprosthetic Joint Infection
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
0
0
David Anderson
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
David Anderson2022-08-15 00:00:212022-09-26 12:51:38Epiaxis Therapeutics & Peptilogics Enter Strategic Drug Discovery Partnership
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
0
0
eallison
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
eallison2022-08-09 17:32:442022-08-09 17:46:13Peptilogics Strengthens Leadership Team with Executive Appointments
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
0
0
David Anderson
/wp-content/uploads/peptilogics_inline_ko_rgb_72-300x79.png
David Anderson2022-08-05 12:17:242022-08-05 12:20:26Peptilogics to Participate in Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting in Pittsburgh
Scroll to top
